SOPH
SOPH
NASDAQ · Health Care

Sophia Genetics Sa

$8.32
+0.08 (+0.97%)
As of Sep 22, 3:20 PM ET ·
Financial Highlights (FY 2026)
Revenue
94.20M
Net Income
-96,307,320
Gross Margin
67.4%
Profit Margin
-102.2%
Rev Growth
+17.6%
D/E Ratio
1.34
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.4% 67.4% 37.1% 37.1%
Operating Margin -91.8% -82.6% 15.7% 15.5%
Profit Margin -102.2% -97.1% 12.0% 14.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 94.20M 80.13M 148.95M 128.31M
Gross Profit 63.49M 54.01M 55.31M 47.64M
Operating Income -86,437,500 -66,173,656 23.40M 19.86M
Net Income -96,307,320 -73,729,659 17.87M 18.85M
Gross Margin 67.4% 67.4% 37.1% 37.1%
Operating Margin -91.8% -82.6% 15.7% 15.5%
Profit Margin -102.2% -97.1% 12.0% 14.7%
Rev Growth +17.6% +17.6% -3.7% -9.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 193.81M 193.81M 123.79M 131.89M
Total Equity 144.99M 144.99M 159.52M 160.29M
D/E Ratio 1.34 1.34 0.78 0.82
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -81,594,045 -65,935,983 34.80M 29.87M
Free Cash Flow 26.94M 20.01M